Lantheus Holdings Inc
NASDAQ:LNTH
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
51.07
123.62
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Lantheus Holdings Inc
Lantheus Holdings Inc
Revenue
Lantheus Holdings Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Revenue
$1.5B
|
CAGR 3-Years
57%
|
CAGR 5-Years
34%
|
CAGR 10-Years
18%
|
|
|
Haemonetics Corp
NYSE:HAE
|
Revenue
$1.4B
|
CAGR 3-Years
13%
|
CAGR 5-Years
7%
|
CAGR 10-Years
4%
|
|
|
DENTSPLY SIRONA Inc
NASDAQ:XRAY
|
Revenue
$3.9B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
3%
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Revenue
$2.3B
|
CAGR 3-Years
22%
|
CAGR 5-Years
13%
|
CAGR 10-Years
23%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Revenue
$4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
12%
|
CAGR 10-Years
18%
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Revenue
$1.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
10%
|
|
Lantheus Holdings Inc
Revenue Breakdown
Breakdown by Geography
Lantheus Holdings Inc
Breakdown by Segments
Lantheus Holdings Inc
|
Total Revenue:
1.3B
USD
|
|
Product Revenue, Net:
1.3B
USD
|
|
Total Radiopharmaceutical Oncology:
854.4m
USD
|
|
Pylarify:
851.3m
USD
|
|
Total Precision Diagnostics:
390.1m
USD
|
|
Definity:
279.8m
USD
|
|
Technelite:
87.4m
USD
|
|
Strategic Partnerships And Other Revenue:
51.9m
USD
|
|
License And Royalty Revenues:
33.4m
USD
|
Lantheus Holdings Inc
Glance View
Lantheus Holdings Inc. is a dynamic healthcare company specializing in the development, manufacture, and commercialization of innovative diagnostic imaging agents, particularly in the field of nuclear medicine. Founded in 1956, the company has established a solid reputation for improving patient care through advanced diagnostics, helping healthcare providers make more informed decisions. Lantheus is perhaps best known for its flagship products, including nuclear imaging agents like Pylarify, used in the detection of prostate cancer. With a robust pipeline of novel radiopharmaceuticals in various stages of development, the company is strategically positioned to address unmet needs in diagnostics and therapeutics, thereby enhancing both patient outcomes and shareholder value. For investors, Lantheus represents a compelling opportunity, particularly as the demand for precision medicine continues to grow. With healthcare trends increasingly leaning towards personalized treatment, Lantheus is poised to grow through strategic partnerships, expanding market access, and leveraging new technologies. The company's commitment to innovation is underscored by its recent achievements and promising clinical trials, which have the potential to reshape the landscape of cancer diagnostics and treatment. As Lantheus Holdings continues to expand its portfolio and strengthen its market presence, investors can look forward to both solid financial performance and meaningful contributions to the evolving field of medical diagnostics.
See Also
What is Lantheus Holdings Inc's Revenue?
Revenue
1.5B
USD
Based on the financial report for Sep 30, 2024, Lantheus Holdings Inc's Revenue amounts to 1.5B USD.
What is Lantheus Holdings Inc's Revenue growth rate?
Revenue CAGR 10Y
18%
Over the last year, the Revenue growth was 24%. The average annual Revenue growth rates for Lantheus Holdings Inc have been 57% over the past three years , 34% over the past five years , and 18% over the past ten years .
You don't have any saved screeners yet
